Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData.
Market research
“The deal activity can provide a useful indication of which biosimilar drugs are in development,” commented Lisa Marris, healthcare analyst at GlobalData. “The recent strategic alliance deals show the potential of bringing these biosimilar monoclonal antibodies to market for therapy areas such as cancer or autoimmune diseases.”